Results 51 to 60 of about 18,508 (192)

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Viruses
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults.
Mark Underwood, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, Jörg Sievers   +9 more
doaj   +1 more source

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

The Lancet Global Health, 2018
Summary: Background: Global rollout of dolutegravir-based antiretroviral therapy (ART) has been hampered in part by insufficient safety data in pregnancy.
Rebecca Zash, MD, Denise L Jacobson, PhD, Modiegi Diseko, BA, Gloria Mayondi, BSc, Mompati Mmalane, MD, Max Essex, ProfPhD, Tendani Gaolethe, MD, Chipo Petlo, BA, Shahin Lockman, MD, Lewis B Holmes, MD, Joseph Makhema, MBBS, Roger L Shapiro, MD   +11 more
doaj   +1 more source

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus

SAGE Open Medical Case Reports, 2022
HIV-infected people have started to live longer since the introduction of antiretroviral therapy, however various co-morbid illnesses have emerged. Three HIV-infected individuals, all at least 43 years old, reported with a new onset of type 2 diabetes ...
Agete Tadewos Hirigo, Selamawit Gutema, Aberash Eifa, Worku Ketema   +3 more
doaj   +1 more source

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

International Journal of Infectious Diseases, 2021
Objectives: The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART).
Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Aristine Cheng, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung   +9 more
doaj   +1 more source

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS [PDF]

, 2015
Huda Taha,1 Archik Das,2 Satyajit Das1,3 1Integrated Sexual Health Service Coventry and Warwickshire Partnership NHS Trust, Coventry, 2School of Medicine, Birmingham University, Birmingham, 3Coventry University, Coventry, UK Abstract: Dolutegravir (DTG)
Das, A., Das, S., Taha, H.
core   +3 more sources

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study

Heliyon
Background: Recently, dolutegravir-based therapy has become the first-line treatment when compared to others. However, dolutegravir-associated side effects in the liver and levels of efficacy haven't been addressed yet in underdeveloped countries such as
Enyew Fenta Mengistu, Dr Tabarak Malik, Meseret Derbew Molla, Adane Adugna, Mohammed Jemal   +4 more
doaj   +1 more source

Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance [PDF]

, 2017
[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV.
Balboa Barreiro, Vanesa, Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Fernández-Bargiela, Noelia, Llibre, Josep M., Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Pernas, Berta, Poveda, Eva   +8 more
core   +2 more sources

Prevalence of low‐level viremia and its association with virological failure among adolescents living with HIV in Eastern Cape, South Africa

HIV Medicine, EarlyView.
Abstract Objectives Low‐level viremia (LLV) has been associated with an increased risk of virological failure among adults on antiretroviral therapy (ART). However, evidence on the clinical implications of LLV among adolescents living with HIV remains limited.
Zea Leon, Olanrewaju Edun, Siyanai Zhou, Janke Tolmay, Lucie Cluver, Gayle Sherman, Ahmad H. Mazanderani, Elona Toska   +7 more
wiley   +1 more source

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic, Antonia Pugliese, Michela Belli, Gian Luca Lonardi, Caterina Ruffilli, Tommaso Albano, Marco Visicaro, Martina Ricciardetto, Pierluigi De Cosmo, Chiara Mussi, Francesca Gandolfi, Cristina Mussini, Costantino Grana, Giovanni Guaraldi   +13 more
wiley   +1 more source